Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
Portfolio Pulse from
Gritstone bio has announced positive updates on its Phase 2 GRANITE study, showing a 27% risk reduction in progression or death in the treated population and a 50% reduction in a specific subgroup. This strengthens the potential of their cancer treatment.
November 11, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gritstone bio's Phase 2 GRANITE study shows promising results with a 27% risk reduction in progression or death in the treated population and 50% in a low ctDNA subgroup, potentially boosting investor confidence.
The positive results from the Phase 2 GRANITE study indicate a significant advancement in Gritstone bio's cancer treatment, likely increasing investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100